Multiple myeloma (MM) arises from malignant immunoglobulin-secreting plasma cells and remains an incurable, often lethal disease despite recent therapeutic advances. The unfoldedprotein response sensor IRE1a supports protein secretion by deploying a kinaseendoribonuclease module to activate the transcription factor XBP1s. MM cells may coopt the IRE1a-XBP1s pathway; however, the validity of IRE1a as a potential MM therapeutic target is controversial. Here we show that genetic disruption of IRE1a or XBP1s, or pharmacologic IRE1a kinase inhibition, attenuated subcutaneous or orthometastatic growth of MM tumors in mice, and augmented efficacy of two well-established frontline antimyeloma agents, bortezomib or lenalidomide. Mechanistically, IRE1a perturbation inhibited expression of key components of the ER-associated degradation machinery, as well as cytokines and chemokines known to promote MM growth. Selective IRE1a kinase inhibition reduced viability of CD138 + plasma cells while sparing CD138cells from bone marrow of newly diagnosed MM patients or patients whose disease relapsed after 1 -4 lines of treatment in both US-and EU-based cohorts. IRE1a inhibition preserved survival and glucose-induced insulin secretion by pancreatic microislets.
Introduction
MM is the second most common human hematologic cancer. It carries a lifetime risk of 0.7% and occurs mainly in older individuals. MM is caused by bone marrow infiltration of malignant, monoclonal immunoglobulin (Ig-)-secreting plasma cells (1) . Despite significant therapeutic advances-including proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and anti-CD38 antibodies-MM remains mainly incurable, with acquired resistance to all available agents, and 5-year survival of 49% (2) . Hence, considering the rapid growth of the aging population in many countries, there is an urgent need for development of novel MM therapies.
The endoplasmic reticulum (ER) assures the precise folding of newly synthesized transmembrane and secreted proteins. Upon elevations in cellular demand for protein secretionfor example, when mature B cells differentiate into Ig-secreting plasma cells-insufficient ER capacity causes accumulation of unfolded proteins (UPs) in the ER lumen. This activates a rheostatic sensing-signaling network-dubbed the unfolded protein response (UPR)-to orchestrate ER adaptation and reestablish cellular homeostasis (3) (4) (5) (6) . The mammalian UPR employs three pivotal ER-resident transmembrane sensors: inositol-requiring enzyme 1 alpha (IRE1a), protein kinase-like endoplasmic reticulum kinase (PERK), and activating transcription factor-6 (ATF6). Detection of excess UPs by the ER lumenal domain of each sensor engages its cytoplasmic moiety to expand the ER and its protein folding and degradative capacities, thus alleviating ER stress. If this corrective response fails and stress becomes overwhelming, the UPR can trigger apoptosis (7) . Conserved from yeast to primates, IRE1a harbors lumenal, transmembrane and cytosolic regions: The cytoplasmic part contains two tandem catalytic modules: A serine/threonine kinase and an endoribonuclease (RNase) (8, 9) . IRE1a activation involves homodimerization, trans-autophosphorylation of the cytoplasmic kinase domain, and RNase activation (9) (10) (11) (12) . The RNase triggers non-conventional splicing of the mRNA encoding X-box protein 1 (XBP1) by removing a 26-nucleotide intron to produce spliced XBP1 (XBP1s) (13) . XBP1s encodes a potent transcription factor that activates multiple genes encoding chaperones, disulfide isomerases and lipid synthases, thereby facilitating biochemical and biophysical expansion of the ER (14) (15) (16) . Additional XBP1s gene-targets encode components of the ER-associated degradation (ERAD) machinery, which promotes retro-translocation of UPs into the cytoplasm, followed by their ubiquitination and proteasomal disposal (14, 17) . An additional activity of IRE1a's RNase-termed regulated IRE1-dependent RNA decay (RIDD)-cleaves ER-associated mRNAs, temporarily abating translational load (18, 19) and suppressing apoptosis (20, 21) , which allows time for cellular adaptation.
Because plasma-cell differentiation requires IRE1a and XBP1s (22) (23) (24) , and because cancer cells often coopt normal stress-response pathways to support malignant growth in hostile microenvironments (25) , it has been proposed that the IRE1a-XBP1s pathway may represent a therapeutically useful vulnerability in MM cells (26) (27) (28) . Supporting this hypothesis, transgenic expression of XBP1s in B cells drove a MM-like disease in mice (29) and high XBP1s levels correlated with worse prognosis in MM patients (30) . XBP1s depletion by shRNA attenuated growth of certain MM cell lines in vitro, and small-molecule inhibition of IRE1a's RNase activity with salicylaldehyde compounds attenuated human MM xenograft growth in mice (31, 32) . Standard-of-care agents such as PIs are effective in MM therapy likely because their inhibition of the 26S proteasome creates a backlog of ERAD substrates that cannot be efficiently degraded, thereby exacerbating ER stress (33) . However, conflicting evidence suggests either positive (33, 34) or negative (35) correlations between XBP1s levels and MM responsiveness to PI therapy. Moreover, although IRE1a kinase inhibition blocked XBP1s production, it failed to attenuate MM cell growth in vitro (36) . An additional concern is that the selectivity of the highly protein-reactive salicylaldehyde-based IRE1a RNase inhibitors is difficult to ascertain: indeed, recent evidence demonstrates that one of these compounds causes oxidative stress due to offtarget activity (37) . Thus, whether IRE1a can be targeted effectively and safely to inhibit malignant MM growth remains controversial. In addition, because XBP1s depletion drives hyper-phosphorylation of IRE1a (20, 38) , alternative, XBP1s-independent IRE1a functionsfor example, activation of c-Jun N-terminal kinase (JNK) (39)-also may impact MM cells.
Another key question that remains unanswered in this context is whether IRE1a can be targeted effectively and safely via its kinase domain to inhibit MM.
Our present results demonstrate that the IRE1a-XBP1s pathway plays a critical role in supporting MM cell growth in vitro in 3D culture, as well as in vivo in subcutaneous and orthometastatic tumor xenograft settings. Selective small-molecule IRE1a kinase inhibition reduced viability of patient-derived malignant MM cells yet spared accompanying normal cells from bone marrow samples, and also preserved insulin secretion by pancreatic microislets.
Together, these findings establish a compelling rationale for developing small-molecule inhibitors targeting IRE1a kinase for MM therapy. suggesting frequent IRE1a-XBP1s pathway activation in MM cells. To investigate the importance of IRE1a for MM cell growth, we first used a doxycycline-(Dox-) inducible shRNA-based knockdown approach. As expected, Dox-driven anti-IRE1a shRNA expression markedly decreased IRE1a and XBP1s protein levels in KMS11, OPM2 and RPMI8226 MM cells ( Fig. 1B) . Importantly, Dox-induced IRE1a depletion markedly inhibited 3D growth of these three cell lines in the form of single spheroids on ultra-low attachment plates, as evident by fluorescence imaging (Fig. 1C-H cells (data not shown). In concert with the growth inhibition, IRE1a depletion in KMS11 cells cultured on matrigel led to a substantial and specific loss of viability, as measured by a CellTiterGlo ® assay (SI Appendix, Fig. S1F-H) . Thus, three genetically diverse MM cell lines (40) displayed significant dependence on IRE1a for 3D growth-a modality that more faithfully reflects in vivo tumor settings than the conventional 2D culture used in earlier work (36) .
Results

Depletion of
Genetic disruption of IRE1a or XBP1s attenuates growth of subcutaneous human MM
xenografts. We next disrupted the IRE1a gene in KMS11 cells using CRISPR/Cas9 gene editing. In contrast to parental KMS11 cells, three independent IRE1a KO clones showed a complete absence of IRE1a protein and failed to upregulate XBP1s in response to the ER stressor thapsigargin (Tg) (SI Appendix, Fig. S2A ). Upon subcutaneous injection into C.B-17 SCID mice, wildtype (WT) KMS11 cells formed readily palpable tumors that reached a mean volume of ~500 mm 3 by 29 days; in contrast, all three IRE1a KO KMS11 clones failed to sustain appreciable tumor growth ( Fig. 2A; SI Appendix, Fig. S2B ). Thus, subcutaneous establishment and growth of KMS11 MM xenografts in mice requires IRE1a.
To examine the relative importance of XBP1s for MM tumor growth, we disrupted the XBP1 gene by CRISPR/Cas9 in KMS11 cells. Similar to the IRE1a KO clones, two independent XBP1 KO clones failed to grow appreciably upon subcutaneous injection into Cb.17-SCID mice, while parental WT cells formed tumors as expected ( Fig. 2B; SI Appendix, Fig. S2C ). Thus, in vivo growth of KMS11 xenografts requires XBP1s. Mechanistically, IRE1a KO decreased the in vitro mRNA levels of several XBP1s target genes encoding key components of the cellular ERAD machinery (14, 17) , i.e., the E3 ubiquitin ligase SYVN1, the E2 ubiquitin-conjugating enzyme UBE2J1, and factors required for the recognition and extraction of terminally misfolded proteins from the ER, such as EDEM1, DERL2, VIMP, DNAJC10, and ERLEC1 (SI Appendix, To ascertain whether IRE1a depletion alone or in combination with standard anti-MM therapies affects growth of pre-established tumors, we allowed subcutaneously implanted KMS11 or RPMI8226 cells carrying Dox-inducible IRE1a shRNAs to form palpable tumors of ~200 mm 3 , and only then induced depletion by Dox treatment. IRE1a knockdown substantially suppressed tumor progression, in conjunction with a marked decrease in XBP1s protein levels; this led to 61% tumor-growth inhibition (TGI) in KMS11 and 70% TGI in RPMI8226 xenografts Similarly, treatment in the RPMI8226 model with the MTD of the IMiD lenalidomide led to 61% TGI, while the combination of IRE1a depletion with lenalidomide achieved 110% TGI (p<0.01 compared to IRE1a knockdown alone) ( Fig. 2E; SI Appendix, Fig. S2G ), indicating complete tumor suppression or regression. Together, these results show that genetic disruption of IRE1a markedly inhibits MM tumor initiation and progression, and increases sensitivity to established agents. Clinically, the perturbation of IRE1a has the potential to cooperate significantly with existing treatment modalities to enhance the efficacy of anti-MM therapy.
Small-molecule inhibition of IRE1a kinase attenuates subcutaneous and orthometastatic
growth of human MM xenografts. Next, we investigated whether pharmacologic inhibition of IRE1α could recapitulate the impact of genetic disruption on MM tumor growth. Because XBP1s depletion through direct IRE1a RNase inhibition can lead to hyper-phosphorylation of the kinase domain (20, 42) , we chose to block IRE1a further upstream, at its kinase level. To test whether IRE1a auto-phosphorylation controls RNase activation in MM cells, we transfected KMS11 IRE1a KO cells with cDNA expression plasmids encoding WT or mutant variants of IRE1a enzymatically deficient in kinase activity (D688N) or auto-phosphorylation on the kinaseactivation loop (S724A S726A S729A triple mutant). Upon ER stress, cells expressing WT IRE1a, but not the kinase-dead or auto-phosphorylation-deficient mutants, displayed elevated production of XBP1s mRNA and protein ( Fig. 3A) . Thus, disruption of either the kinase function or the auto-phosphorylation sites of IRE1a in MM cells blocks RNase activation and XBP1s production.
Harrington et al (36) identified kinome-selective inhibitors of IRE1a kinase, including compounds 16 and 18. We synthesized both molecules and confirmed their binding to a recombinant IRE1a protein comprising the kinase and RNase domains, and their ability to inhibit its RNase activity toward a synthetic XBP1-based RNA substrate, as well as cellular IRE1a activity measured by an XBP1s-luciferase reporter assay (SI Appendix, Fig. S3A ) (11, 24) . We compared the kinase selectivity of these compounds by testing 220 kinases via To gain structural insight into the interaction of compound 18 with its target, we co- (Fig. 3D) , where residue Y628 shows the most difference in sidechain conformation. Although we cannot rule out that crystal packing may influence this, structural changes in the Ca-helix may contribute to the improved selectivity of 18 against IRE1a: We therefore chose the latter molecule as a tool for further studies. Fig. S4A ). These data suggested potentially sufficient exposure to this compound to attain significant, though perhaps incomplete, IRE1a inhibition in vivo. Comparable to the effect of IRE1a shRNA depletion, treatment of mice bearing pre-established KMS11 or OPM2 tumors with 18 over 23 or 11 days, respectively, led to a substantial reduction in XBP1s protein, in conjunction with 51% or 70% TGI, respectively ( Fig. 4A and B; SI Appendix, Fig. S4B-E) .
Thus, pharmacologic IRE1a kinase inhibition recapitulated the impact of shRNA-based IRE1a disruption on growth of MM xenografts.
We then turned to a more stringent orthometastatic model 
IRE1a kinase inhibition reduces viability of patient-derived MM cells while sparing
normal cells. MM cell lines may acquire further genetic or epigenetic alterations upon prolonged passage that could diverge from primary MM cells. Therefore, to gain a more direct appraisal of the importance of IRE1a for primary MM cell survival, we tested the effect of compound 18 on viability of primary CD138 + MM cells, from bone marrow or peripheral blood samples donated by MM patients treated in the USA and EU (SI Appendix, Fig. S5A ). Incubation over two days with 18 led to marked reductions in viability of the malignant CD138 + MM cells, but not the associated non-malignant CD138cells, in the majority of MM samples ( Fig. 5A and B) .
Samples in both cohorts from newly diagnosed patients as well as subjects whose MM relapsed after 1-4 prior lines of therapy showed dose-dependent sensitivity to 18 ( Fig. 5C and D) . Four additional relapsed MM samples did not show significant loss of viability (data not shown).
Importantly, exposure to 18 did not reduce the viability of CD138 + cells from three nonmalignant bone marrow aspirates ( Fig. 5E) . Thus, IRE1a kinase inhibition can selectively disrupt survival of primary malignant MM cells while sparing nonmalignant marrow cells, including plasma cells. The impact on both naiive and post-treatment relapsed MM samples suggests that IRE1a inhibition has the potential to provide clinical benefit across multiple lines of therapy.
Inducible gene-knockout studies in mice have suggested that the IRE1a-XBP1s pathway may support insulin secretion by pancreatic cells (44, 45). To examine whether pharmacologic IRE1a kinase inhibition would affect these cell types, we first verified the ability of compound 18 to inhibit XBP1s induction in human pancreatic islet 3D microtissues, which contain all the endocrine cell types and can retain viability and function in culture for up to 4 weeks (46). At 2.4 µM, 18 suppressed Tg-induced XBP1s production to baseline levels ( Fig. 6A) , confirming effective IRE1a pathway inhibition. Importantly, 18 did not decrease viability, nor did it perturb glucose-stimulated insulin secretion even at higher concentrations up to 7.5 µM ( Fig. 6B and C) .
We obtained similar results with rat pancreatic microislets (SI Appendix, Fig. S6A and B) .
Together, these results suggest that IRE1a kinase inhibition may achieve significant MM tumor disruption without overt negative effects on pancreatic endocrine homeostasis.
Discussion
It has been proposed that MM cells may coopt the IRE1a-XBP1s pathway to mitigate persistent ER stress, caused by excessive Ig production and a nutrient/oxygen-poor bone marrow microenvironment (27) . However, recent studies have raised significant doubt concerning the validity of IRE1a as a potential therapeutic target: Lowered levels of XBP1s correlated with PI resistance in MM cells (35) , and IRE1a kinase inhibition blocked XBP1s yet did not affect MM cell viability in 2D culture (35, 36) . Moreover, loss-of-function studies directly and specifically addressing the importance of IRE1a's kinase module for MM growth have been lacking.
Although work based on salicylaldehyde small-molecule RNase inhibitors supported a protumorigenic role of IRE1a in MM (31, 32) , a key caveat is that such compounds are highly protein-reactive, and their selectivity versus other RNases and other targets is likely to be poor (37) .
To interrogate the requirement of IRE1a for MM growth, we employed a series of strategies to disrupt it at the gene, transcript, or kinase level, in diverse model systems. Our in vitro studies showed that IRE1a depletion by shRNA markedly attenuates growth of several MM cell lines in 3D spheroid settings-a scenario that was not previously investigated. Both IRE1a Mechanistically, IRE1a knockdown decreased mRNA expression of specific ERAD components known to be induced by XBP1s, and it compromised the ability of MM cells to secrete Ig as well as several important cytokines and chemokines, some of which have previously been shown to support malignant plasma cell growth in vitro and in vivo (1, 23, 33, 41) . Remarkably, the extent of TGI was comparable between IRE1a knockdown and the well-established frontline MM therapy agents bortezomib or lenalidomide. Furthermore, combination of IRE1a depletion with bortezomib or lenalidomide significantly increased the extent of TGI as compared to respective monotherapies. Together, these results suggest that IRE1a inhibition may provide clinical benefit, either alone or in combination with other MM therapies known to disrupt protein homeostasis (33, 47) .
To examine more directly the requirement for IRE1a's kinase moiety, we first confirmed its importance for RNase activation by mutational perturbation of the kinase catalytic core or its target autophosphorylation sites. We then evaluated two compounds that bind to IRE1a's ATP docking site and exert allosteric inhibition of RNase activation (36) . One of these showed an improved ability to displace the Ca helix in the kinase domain, with excellent selectivity toward In conclusion, our studies provide definitive preclinical evidence validating IRE1a as a potential therapeutic target for MM. IRE1a may play an important role in augmenting malignant growth of MM cells by enabling their adaptation to chronic ER stress through elevated ERAD capacity. IRE1a may also support the secretion of cytokines and chemokines that enable survival and growth of malignant MM cells in their metabolically restrictive bone marrow microenvironment. Finally, our findings provide proof of concept that the kinase domain of IRE1a is an effective and potentially safe lever for small-molecule inhibition of this dualfunction enzyme both in vitro and in vivo. This work therefore presents a compelling rationale to develop clinical-grade IRE1a kinase-disrupting agents for MM therapy.
Material and Methods
Detailed methods are provided in SI Appendix. 3D spheroid proliferation assays. RPMI8226 IRE1a sh7-5-mCherry, OPM2 IRE1a sh9-mCherry and KMS11a IRE1 sh8-9-mCherry cells were pre-treated with 0.5 µg/ml doxycycline for 3 days before plating 1000 cells/ well in ultra-low attachment (ULA) 96-well plates (Corning). Single tumor spheroids were formed by centrifugation (1,000 rpm) for 10 min according to manufacturer's protocol. Spheroids were imaged using a real-time imaging system (IncuCyte™, Essen Bioscience, Ann Arbor, Michigan). Frames were captured at 4-hr intervals using a 4x or 10x objective and red fluorescence was detected.
For Matrigel assays, KMS11 IRE1a sh8-9 cells were pre-treated with 0.5 µg/ml doxycycline for 3 days before plating 1000-5000 cells/well on 50 µl/well of Matrigel (Corning) into 96 well plates according to manufacturer's protocol. Spheroids images were captured at 4-hr intervals using a 10x objective. Cell viability was assessed using an ATP-consumption assay (CellTiter-Glo® 3D, Promega) and measured in a luminescence reader (Envision, Perkin Elmer).
Cultures were maintained at 37 °C throughout and run at least in triplicates. Values well were pooled and averaged across all replicates.
Pancreatic islet 3D microtissue assays. Human and rodent 3D InSight™ pancreatic islet microtissues (InSphero AG) were produced from reconstituted dispersed human or rat pancreatic islet cells in a modified manner as described previously (46) for 48 hr. MM cells were then identified using CD138-PE staining and cell death was assessed by the loss of CD138 staining as previously described (48). MM or normal plasma cells were identified as CD19 -, CD45 -/dim, CD38 + , CD138 + , and CD46 + . For efficacy studies, 10x10 6 KMS11 IRE1a sh8-9, RPMI8226 IRE1a sh5-7 or OPM2 IRE1a sh9 cells were prepared and subcutaneously inoculated as outlined above. Tumors were monitored until they reached a mean tumor volume of approximately 150 to 300 mm 3 . For efficacy studies of IRE1 shRNA knockdown in combination with standard of care agents, bortezomib (Velcade®, Millennium Pharmaceuticals) or lenalidomide (Revlimid®, Celgene Corp.), animals were randomized into the following treatment groups: (i) 5% sucrose water (provided in drinking water, changed weekly); (ii) doxycycline (0.5 mg/ml, dissolved in 5% sucrose water, changed 3x/ week); (iii) bortezomib (0.75 mg/kg, 100 µL total, intravenously, twice per week) or lenalidomide (50mg/kg, 100 µL total, intraperitoneally, once daily for 5 consecutive days), respectively; and (iv) combination of doxycycline plus bortezomib, or doxycycline plus lenalidomide, respectively.
Subcutaneous xenograft growth and efficacy studies.
For the compound 18 efficacy studies, animals were randomized into one of three following treatment groups: (i) vehicle controls (35% PEG400 and 10% EtOH in water, 100 µL total, intraperitoneally, dosed once daily) and 5% sucrose water (provided as drinking water, Comparison of three or more columns was performed using a one-way ANOVA followed by Turkey's procedure. A P value < 0.05 was considered significant. All statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc.). For further information regarding statistical analysis, please see section regarding xenograft studies above. (17):4562-4573. 
Figure legends
